CG at a glance
Carlyle Group reported 16 positions worth $8.4 billion in its 13F-HR for Q3 2026, filed November 6, 2026. Its largest holdings were Medline Inc (MDLN) at 77.6%, Standardaero Inc (SARO) at 21.6% and Phathom Pharmaceuticals Inc (PHAT) at 0.3%.
- Versus Q2 2026, it opened 0 new positions, added to 2, trimmed 1 and sold out of 3. Reported portfolio value went from $10.0 billion to $8.4 billion.
- The 10 largest positions made up 100.0% of the reported portfolio.
- Largest estimated buys in Q3 2026: Robinhood Mkts Inc (HOOD) (added, about $454,000) and Ramaco Res Inc (METC) (added, about $258,000).
- For the fiscal year ended December 31, 2025 (FY2025), Carlyle Group (CG) reported revenue of $4.8 billion (down 11.9% from FY2024) and net income of $808.7 million. Diluted EPS was $2.18.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Carlyle Group (CG) shares worth $3.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Rubenstein David M. on September 11, 2026 of 400,000 shares at $42.74 per share.
- In the last 90 days, CG insiders reported 0 open-market purchases ($0) and 1 open-market sale ($17.1M) on Form 4, a net sale of $17.1M.
Source: 13F-HR filings on SEC EDGAR.
- 13F portfolio · Q3 2026
- $8.4B
- −16.4% vs prior quarter
- Positions
- 16
- 0 new · 3 sold out
- Top 10 weight
- 100.0%
- Concentration of the 13F book
- Turnover
- 0%
- Quarter-over-quarter
- Revenue · FY2025
- $4.8B
- −11.9% vs prior year
- 13F holders
- 35 funds
- $3.7B · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
Carlyle Group top 13F holdings, Q3 2026
Largest reported positions by market value, from the 13F-HR filed Nov 6, 2026
| # | Company | Weight | Value | Shares | vs Q2 2026 |
|---|---|---|---|---|---|
| 1 | Medline IncMDLN | 77.64% | $6.5B | 187,083,713 | Held |
| 2 | Standardaero IncSARO | 21.60% | $1.8B | 84,587,035 | Held |
| 3 | Phathom Pharmaceuticals IncPHAT | 0.30% | $25.5M | 3,496,808 | Held |
| 4 | Pony Ai IncPONY | 0.18% | $15.4M | 2,362,447 | Held |
| 5 | Invitation Homes IncINVH | 0.15% | $12.6M | 477,500 | Trimmed |
| 6 | Spruce Biosciences Inc | 0.02% | $1.9M | 38,620 | Held |
| 7 | Forward Air Corp | 0.02% | $1.6M | 107,214 | Held |
| 8 | Adicet Bio IncACET | 0.02% | $1.3M | 184,295 | Held |
| 9 | Robinhood Mkts IncHOOD | 0.01% | $986K | 8,767 | Added |
| 10 | Krispy Kreme IncDNUT | 0.01% | $978K | 340,748 | Held |
| 11 | Onkure Therapeutics Inc | 0.01% | $735K | 269,895 | Held |
| 12 | SunPower Inc | 0.01% | $720K | 2,343,750 | Held |
| 13 | Jasper Therapeutics Inc | 0.01% | $618K | 1,066,189 | Held |
| 14 | Ramaco Res IncMETC | 0.01% | $438K | 52,922 | Added |
| 15 | Nebius Group N.V.NBIS | 0.01% | $435K | 1,846 | Held |
| 16 | N-able IncNABL | 0.01% | $384K | 93,732 | Held |
Source: Carlyle Group 13F-HR on SEC EDGAR. Long equity positions only (put and call options excluded); weights are shares of the reported 13F portfolio, not total assets. How 13F filings work
Carlyle Group biggest buys and sells, Q3 2026
Largest estimated position changes versus Q2 2026
| Company | Move | Est. flow | Shares now | Weight now |
|---|---|---|---|---|
| Getty Images Holdings IncGETY | Sold out | −$5.4M | 0 | - |
| Invitation Homes IncINVH | Trimmed | −$4.9M | 477,500 | 0.15% |
| Q32 Bio Inc | Sold out | −$769K | 0 | - |
| Riley Exploration Permian InREPX | Sold out | −$530K | 0 | - |
| Robinhood Mkts IncHOOD | Added | +$454K | 8,767 | 0.01% |
| Ramaco Res IncMETC | Added | +$258K | 52,922 | 0.01% |
Estimated flow = change in share count × quarter-end price (0 new, 2 added, 1 trimmed, 3 sold out). 13F reports show holdings on the last day of the quarter, not the trade dates.
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Liabilities $21.0B at June 30, down $1.1B from December 31, 2025
- Cash and equivalents $1.3B excluding Consolidated Funds
- Six-month share repurchases 7.9M shares, reducing outstanding shares to 353.4M
- Unfunded Carlyle fund commitments $4.3B, with $3.4B subscribed by professionals
- Contingent Abingworth payments up to $130.0M, with $16.1M accrued at June 30, 2026
Risk Factors
- Share-repurchase authorization reset to $2.0 billion effective February 26, 2026
- $1,630.9 million repurchase authorization remained as of June 30, 2026
- 6.6 million shares repurchased during the quarter at disclosed average prices of $46.97 and $44.64
AI summary of the CG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Carlyle reported third-quarter fiscal 2026 results for the period ended September 30, 2026
- Detailed financial results and management commentary available in Exhibits 99.1 and 99.2
Item EX-99.1: Item EX-99.1
- Q3 2026 results: GAAP loss before taxes of $77 million, with a 23.0% margin on loss before taxes
- Distributable earnings per share described as among Carlyle’s strongest quarters on record
Item EX-99.2: Item EX-99.2
- Q3 2026 results covered the quarter ended September 30, 2026, with GAAP loss attributable to Carlyle of $8 million, or $0.02 diluted EPS
- Distributable Earnings reached $433 million, or $1.12 post-tax per share, highlighting stronger cash-oriented earnings despite GAAP losses
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released August 5, 2026
- Detailed financial information available in Exhibits 99.1 and 99.2
Item EX-99.1: Item EX-99.1
- Q2 2026 income before taxes $274 million, with a 24.4% margin
- Record Fee Related Earnings and highest Distributable Earnings in nearly four years, signaling stronger recurring profitability
Item EX-99.2: Item EX-99.2
- Q2 2026 earnings release: Distributable Earnings $472M, or $1.07 per share, supporting stronger shareholder returns
- Fee Related Earnings $358M, up 11% year over year, while FRE margin declined to 47% from 48%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Carlyle held its 2026 Annual Meeting on June 3, 2026
- Item 5.02 indicates officer or compensatory-arrangement disclosures, but the provided excerpt is incomplete
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 13 director nominees elected for one-year terms, with FOR votes ranging from 287.6M to 300.0M
- Ernst & Young ratified as independent auditor for 2026, receiving 325.3M FOR votes versus 7.4M AGAINST
AI summaries of CG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CG
Don't miss the next CG filing
- 13F alerts. A push when CG files a new 13F or a 13D stake.
- Smart Money consensus. Which stocks CG and other tracked funds bought together.
- Ask anything. An AI agent that reads every CG filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Nedelman Jeffrey | F | Nov 1, 2026 | 120,393 | $40.18 |
| Rubenstein David M. | G | Sep 11, 2026 | 100,000 | - |
| Rubenstein David M. | Sell | Sep 11, 2026 | 400,000 | $42.74 |
| LoBue Lindsay | A | Aug 26, 2026 | 2,657 | - |
| SCHWARTZ HARVEY M | A | Aug 26, 2026 | 19,240 | - |
| Heinzelman Kate Elizabeth | A | Aug 26, 2026 | 78 | - |
| Jenkins Mark David | A | Aug 26, 2026 | 6,264 | - |
| Nedelman Jeffrey | A | Aug 26, 2026 | 6,615 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $3.0B | $5.4B | $4.8B |
| Net Income | -$608.4M | $1.0B | $808.7M |
| Net Margin | -20.5% | 18.8% | 16.9% |
| Balance Sheet | |||
| Total Assets | $21.2B | $23.1B | $29.1B |
| Equity | - | $6.3B | $7.1B |
| ROE | - | 16.1% | 11.5% |
| Per Share | |||
| EPS | $-1.68 | $2.77 | $2.18 |
| Cash Flow | |||
| Operating CF | $204.9M | -$759.5M | -$3.3B |
| CapEx | $66.6M | $77.7M | $99.4M |
Source: XBRL data in Carlyle Group (CG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $3.66B |
| Q2 2026 | 36 | $4.17B |
| Q1 2026 | 35 | $4.97B |
| Q4 2025 | 32 | $6.31B |
| Q3 2025 | 32 | $6.57B |
| Q2 2025 | 31 | $4.98B |
| Q1 2025 | 27 | $3.09B |
| Q4 2024 | 28 | $2.51B |
- Renaissance Technologies LLC+818.1K (+110%)
- Citadel Advisors LLC+692.9K (+83%)
- JPMorgan Chase & Co+179.0K (+17%)
- Millennium Management+138.8K (+78%)
- Morgan Stanley+134.5K (+1%)
- BlackRock−3.30M (-10%)
- Goldman Sachs Group−380.2K (-24%)
- Bank of America Corp−374.6K (-20%)
- Vanguard Portfolio Management LLC−115.2K (-1%)
- Wells Fargo & Co−98.6K (-26%)
- FMR LLC (Fidelity)−4.36M
Source: 13F-HR filings on SEC EDGAR (aggregated from 256 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest Carlyle Group SEC filings
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 13F-HR | Nov 6, 2026 | Sep 30, 2026 | - | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 13F-HR | Aug 7, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - |
Related Financials companies
- ABX · Abacus Global Management, Inc.Investment Advice
- AAMI · Acadian Asset Management Inc.Investment Advice
- AMG · Affiliated Managers Group IncInvestment Advice
- ALTI · AlTi Global, Inc.Investment Advice
- AMP · Ameriprise FinancialInvestment Advice
- APO · Apollo Global ManagementInvestment Advice
- ARES · Ares ManagementInvestment Advice
- APAM · Artisan Partners Asset Management Inc.Investment Advice
CG 13F holdings: frequently asked questions
What stocks does Carlyle Group own?
In its 13F-HR for Q3 2026 (filed November 6, 2026), Carlyle Group reported 16 positions worth $8.4 billion. The largest were Medline Inc (MDLN), 77.6%; Standardaero Inc (SARO), 21.6%; Phathom Pharmaceuticals Inc (PHAT), 0.3%; Pony Ai Inc (PONY), 0.2%; Invitation Homes Inc (INVH), 0.1%. The top 10 positions were 100.0% of the portfolio.
What did Carlyle Group buy in Q3 2026?
Compared with Q2 2026, Carlyle Group's largest estimated purchases were Robinhood Mkts Inc (HOOD) (added, about $454,000) and Ramaco Res Inc (METC) (added, about $258,000). In total it opened 0 new positions and added to 2. Amounts are estimated from share-count changes at quarter-end prices.
What did Carlyle Group sell in Q3 2026?
Compared with Q2 2026, Carlyle Group's largest estimated sales were Getty Images Holdings Inc (GETY) (sold out, about $5.4 million), Invitation Homes Inc (INVH) (trimmed, about $4.9 million), Q32 Bio Inc (sold out, about $769,000) and Riley Exploration Permian In (REPX) (sold out, about $530,000). In total it sold out of 3 positions and trimmed 1.
When does Carlyle Group file 13F reports?
Carlyle Group's latest 13F-HR was filed November 6, 2026 and covers the quarter ended September 30, 2026. 13F-HR reports are due within 45 days of each quarter-end, so the Q4 2026 report is due by February 14, 2027.
Are CG insiders buying or selling?
In the last 90 days, Carlyle Group (CG) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $17.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CG stock?
As of September 30, 2026, the largest Carlyle Group (CG) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), Vanguard Portfolio Management LLC ($464.6 million), Vanguard Capital Management LLC ($451.0 million), Morgan Stanley ($401.7 million), State Street Corp ($397.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CG's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Carlyle Group (CG) reported revenue of $4.8 billion (down 11.9% from FY2024) and net income of $808.7 million. Diluted EPS was $2.18. The figures come from the XBRL data in the 10-K.
What did CG report in its latest 8-K?
Carlyle Group (CG) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Carlyle reported third-quarter fiscal 2026 results for the period ended September 30, 2026.
What are the latest CG SEC filings?
Carlyle Group (CG) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 3, 2026.
What is CG's SEC CIK number?
Carlyle Group (CG)'s SEC Central Index Key (CIK) is 1527166. EDGAR lists every CG filing under that number.
Ask anything about CG
The research agent reads CG's filings, financials, insider trades and 13F holders, then answers with sources.